Scholar Rock Holding Corporation (SRRK) 株式分析

企業概要

Scholar Rock Holding Corporation is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company operates within the Healthcare sector and the Biotechnology industry, focusing on the molecular mechanisms of growth factor activation to improve patient outcomes. With a total market capitalization of $5.74 billion and an employee base of 289, the organization maintains a significant valuation relative to its operational footprint. The market cap figure indicates that the market assigns a substantial premium to the company's pipeline, particularly given that annual revenue data is not currently disclosed in the provided financial records. This valuation suggests high expectations regarding the future commercial potential of its novel therapeutic candidates, as the company has not yet generated sufficient revenue to establish a traditional sales-based valuation multiple. The scale of the enterprise, evidenced by its biotech classification and focus on unmet medical needs, positions it as a specialized player in the rare disease space rather than a broad-line pharmaceutical manufacturer.

財務健全性

The company reported a net income of $-377,939,008 and an EBITDA of $-382,987,000 for the trailing twelve months, while revenue figures are not disclosed in the available data. The substantial gap between the reported net income and EBITDA reflects significant non-operating expenses or interest costs that are impacting the bottom line, although the absence of specific revenue data prevents a precise calculation of operating leverage. Free cash flow stands at $-162,622,256, indicating that the company is currently burning cash to fund research and development activities rather than generating liquidity from operations. The balance sheet shows a cash position of $367.56 million against total debt of $108.92 million, resulting in a debt-to-equity ratio of 44.37. Despite the negative earnings, the current ratio of 6.95 demonstrates a highly conservative liquidity stance, as the company holds significantly more current assets than current liabilities. The gross margin, operating margin, and profit margin are all reported at 0.0%, which is typical for early-stage biotechnology firms that have not yet achieved commercial product sales or have recorded revenues that do not cover direct costs in the reported period. Return on Equity is -123.1% and Return on Assets is -54.7%, metrics that reveal the company is currently utilizing shareholder capital and assets to generate losses rather than positive returns. These negative return metrics are consistent with the business model of a biopharmaceutical company investing heavily in clinical trials before reaching a revenue-generating milestone.

バリュエーション評価

The company does not have a trailing P/E ratio available, while the forward P/E is listed as -23.30, implying that earnings are expected to remain negative in the near term. The price-to-book ratio is 22.09, indicating that the market values the company at more than 22 times its book value, which suggests a high premium assigned to the intangible assets and pipeline value. The price-to-sales ratio and EV/EBITDA are not calculable or are negative at -14.32 due to the lack of positive earnings and disclosed revenue data. The stock has traded between a 52-week high of $51.62 and a 52-week low of $22.71, with the current market price situated within this range reflecting ongoing volatility typical of biotech equities. The beta of 0.69 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to large-cap equities. The negative forward P/E and EV/EBITDA multiples highlight the speculative nature of the valuation, where investors are pricing in future success rather than current profitability. These alternative valuation metrics are standard for pre-commercial biotechnology companies where traditional multiples are not applicable.

Growth & Income

Revenue growth and earnings growth rates are not disclosed in the available facts, preventing a direct comparison of growth rates between the two metrics. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividend payments indicates that the company retains all available earnings, if any, to reinvest into research and development and clinical trial expansion rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by capital appreciation potential rather than current yield, relying entirely on the successful commercialization of its pipeline to eventually generate positive cash flow. The reinvestment strategy is a common characteristic of the biotechnology sector, where companies prioritize long-term innovation over short-term income distribution.